How the natural history of dilated cardiomyopathy has changed. A review of the Registry of Myocardial Diseases of Trieste;Come è cambiata la storia naturale della cardiomiopatia dilatativa. Una revisione del Registro delle Malattie del Miocardio di Trieste

Italian Heart Journal, Supplementi

Volumn 5, Issue 4, 2004, Pages 253-266

  Di Lenarda, Andrea ^a   Pinamonti, Bruno ^a   Mestroni, Luisa ^b   Salvi, Alessandro ^a   Sabbadini, Gastone ^a   Gregori, Dario ^c   Perkan, Andrea ^a   Zecchin, Massimo ^a   Carniel, Elisa ^a   Bussani, Rossana ^d   Silvestri, Furio ^a   Morgera, Tullio ^e   Camerini, Fulvio ^a   Sinagra, Gianfranco ^a   Davanzo, Milla ^f   Di Chiara, Cinzia ^f   Dreas, Lorella ^f   Lardieri, Gerardina ^f   Longaro, Fulvia ^f   Massa, Laura ^f   Miani, Daniela ^f   Moretti, Michele ^f   Pitzorno, Cristina ^f   Rakar, Serena ^f   Scherl, Giulio ^f   Vitali Serdoz, Laura ^f   Zanchi, Cristiana ^f   more..

^a OSPEDALI RIUNITI   (Italy)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF TURIN   (Italy)

^d UNIVERSITY OF TRIESTE   (Italy)

^e Ospedale San Polo   (Italy)

^f NONE

Author keywords

Beta blockers; Dilated cardiomyopathy; Prognosis; Sudden cardiac death

Indexed keywords

CONGESTIVE CARDIOMYOPATHY; HEART ARRHYTHMIA; HEART LEFT VENTRICLE FUNCTION; HUMAN; ITALY; MORTALITY; PATHOPHYSIOLOGY; PROGNOSIS; REGISTER; REVIEW; SUDDEN DEATH; SURVIVAL RATE; TIME;

ARRHYTHMIA; CARDIOMYOPATHY, DILATED; DEATH, SUDDEN, CARDIAC; HUMANS; ITALY; PROGNOSIS; REGISTRIES; SURVIVAL RATE; TIME FACTORS; VENTRICULAR FUNCTION, LEFT;

EID: 6044252067     PISSN: 15903796     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies. Circulation 1996; 93: 841-2.
2. Codd MB, Sugrue DD, Gersh BJ, Melton LJ. Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy. A population-based study in Olmsted County, Minnesota, 1975-1984. Circulation 1989; 80: 564-72.
3. Mestroni L, Rocco C, Gregori D, et al. Familial dilated cardiomyopathy: evidence for genetic and phenotypic heterogeneity. Heart Muscle Disease Study Group. J Am Coll Cardiol 1999; 34: 181-90.
4. Rakar S, Sinagra G, Di Lenarda A, et al. Epidemiology of dilated cardiomyopathy. A prospective post-mortem study of 5252 necropsies. Eur Heart J 1997; 18: 117-23.
5. Gavazzi A, De Maria R, Porcu M, et al. Cardiomiopatia dilatativa: una nuova storia naturale? L'esperienza dello Studio Multicentrico Italiano Cardiomiopatie (SPIC). G Ital Cardiol 1995; 25: 1109-25.
6. Mestroni L, Maisch B, McKenna WJ, et al. Guidelines for the study of familial dilated cardiomyopathies. Collaborative Research Group of the European Human and Capital Mobility Project on Familial Dilated Cardiomyopathy. Eur Heart J 1999; 20: 93-102.
7. Gavazzi A, Lanzarini L, Cornalba C, et al. Dilated (congestive) cardiomyopathy. G Ital Cardiol 1984; 14: 492-8.
8. Franciosa JA, Wilen M, Ziesche S, Cohn JN. Survival in men with severe chronic left ventricular failure due to either coronary heart disease or idiopathic dilated cardiomyopathy. Am J Cardiol 1983; 51: 831-6. (Pubitemid 13141977)
9. Komajda M, Jais JP, Reeves F, et al. Factors predicting mortality in idiopathic dilated cardiomyopathy. Eur Heart J 1990; 11: 824-31.
10. Di Lenarda A, Secoli G, Perkan A, et al. Changing mortality in dilated cardiomyopathy. Br Heart J 1994; 72: 46-51.
11. Fuster V, Gersh BJ, Giuliani ER, et al. The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol 1981; 47: 525-33.
12. Diaz RA, Obasohan A, Oakley CM. Prediction of outcome in dilated cardiomyopathy. Br Heart J 1987; 58: 393-9.
13. Sugrue DD, Rodeheffer RJ, Codd MB, et al. The clinical course of idiopathic dilated cardiomyopathy. A population-based study. Ann Intern Med 1992; 117: 117-23.
14. Di Lenarda A, Hlede S, Sabbadini G, et al. Il miglioramento della prognosi nella cardiomiopatia dilatativa idiopatica: il ruolo della diagnosi precoce e della terapia medica ottimizzata. G Ital Cardiol 1999; 29: 1452-62.
15. Sinagra G, Sabbadini G, Di Lenarda A, et al. Come è cambiata la terapia medica dello scompenso cardiaco alla luce dei grandi trial clinici. Ital Heart J Suppl 2001; 2: 97-115.
16. Di Lenarda A, Sabbadini G, Gortan R, et al. Has the prognosis of idiopathic dilated cardiomyopathy improved in the community? The Heart Muscle Disease Registry of Trieste. (abstr) J Am Coll Cardiol 2001; 37: 169A.
17. Di Lenarda A, Gregori D, Sinagra G, et al. Metoprolol in dilated cardiomyopathy: is it possible to identify factors predictive of improvement? J Card Fail 1996; 2: 87-102.
18. Sinagra G, Boccanelli S, Camerini F, et al. Beta-bloccanti nello scompenso cardiaco. Esperienze e suggerimenti per l'impiego clinico. G Ital Cardiol 1998; 28: 61-70.
19. Di Lenarda A, Goliani P, Grella M, Sabbadini G, Driussi M, Sinagra G. Le statistiche ospedaliere come strumento di studio epidemiologico: lo scompenso cardiaco a Trieste. Ital Heart J Suppl 2002; 3: 58-70.
20. Levy D, Kenchaiah S, Larson M, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002; 347: 1347-402.
21. Massa L, Vitali-Serdoz L, Di Lenarda A, et al. Prognostic stratification and long-term follow-up of optimally treated patients with ischemic cardiomyopathy. The Trieste Heart Failure Registry. (abstr) Eur J Heart Fail 2002; 1 (Suppl 1): 18.
22. Steimle AE, Stevenson LW, Fonarow GC, et al. Prediction of improvement in recent onset cardiomyopathy after referral for heart transplantation. J Am Coll Cardiol 1994; 23: 553-9.
23. Di Lenarda A, Sinagra G, Sabbadini G, et al. Long-term follow-up in asymptomatic dilated cardiomyopathy treated with beta-blockers. The Heart Muscle Disease Registry of Trieste. (abstr) Eur Heart J 2001; 22 (Suppl): 637.
24. Michels VV, Moll PP, Miller FA, et al. The frequency of familial dilated cardiomyopathy in a series of patients with idiopathic dilated cardiomyopathy. N Engl J Med 1992; 326: 77-82.
25. Grunig E, Tasman JA, Kucherer H, Franz W, Kubler W, Katus HA. Frequency and phenotypes of familial dilated cardiomyopathy. J Am Coll Cardiol 1998; 31: 186-94.
26. Gregori D, Rocco C, Miocic S, Mestroni L. Estimating the frequency of familial dilated cardiomyopathy in the presence of misclassification errors. J Appl Stat 2001; 28: 53-62.
27. Sinagra G, Di Lenarda A, Brodsky GL, et al, for the Heart Muscle Disease Study Group. New insights into the molecular basis of familial dilated cardiomyopathy. Ital Heart J 2001; 2: 280-6.
28. Kamisago M, Sharma SD, De Palma SR, et al. Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy. N Engl J Med 2000; 343: 1688-96.
29. Brodsky GL, Muntoni F, Miocic S, Sinagra G, Sewry C, Mestroni L. A lamin A/C gene mutation associated with dilated cardiomyopathy with variable skeletal muscle involvement. Circulation 2000; 101: 473-6. (Pubitemid 30080859)
30. Jacobs PM, Hanson EL, Crispell KA, et al. Novel lamin A/C gene mutations in two families with dilated cardiomyopathy and conduction system disease. J Card Fail 2001; 7: 249-56.
31. Arbustini E, Pilotto A, Repetto A, et al. Autosomal dominant dilated cardiomyopathy with atrioventricular block: a lamin A/C defect-related disease. J Am Coll Cardiol 2002; 39: 981-90. (Pubitemid 34234120)
32. Taylor MR, Fain PR, Sinagra G, et al. Natural history of dilated cardiomyopathy due to lamin A/C gene mutations. J Am Coll Cardiol 2003; 41: 771-80.
33. Cintron G, Johnson G, Francis G, et al. Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure. The V-HeFT VA Cooperative Studies Group. Circulation 1993; 87 (Suppl VI): 17-23.
34. Driussi M, Di Lenarda A, Sabbadini G, et al. Valore prognostico della risposta alla terapia ottimizzata nella cardiomiopatia dilatativa. Il Registro delle Malattie del Miocardio di Trieste. (abstr) Ital Heart J 2001; 2 (Suppl 2): 57.
35. Gortan R, Pinamonti B, Di Lenarda A, Sabbadini G, Driussi M, Sinagra G. Reverse left ventricular remodeling in optimally treated dilated cardiomyopathy. Clinical and prognostic significance. (abstr) Eur J Heart Fail 2002; 4 (Suppl 1): 1.
36. Koelling TM, Aaronson KD, Cody RJ, Bach DS, Armstrong WF. Prognostic significance of mitral regurgitation in patients with left ventricular systolic dysfunction. Am Heart J 2002; 144: 524-9.
37. Pinamonti B, Gortan R, Di Lenarda A, Carniel E, Vitali- Serdoz L, Sinagra G. Functional mitral regurgitation in dilated cardiomyopathy: evolution in tailored medical treatment and prognostic significance. (abstr) Eur J Heart Fail 2002; 4 (Suppl 1): 1.
38. Metra M, Nodari S, Parrinello G, Giubbini R, Manca C, Dei Cas L. Marked improvement in left ventricular ejection fraction during long-term beta-blockade in patients with chronic heart failure: clinical correlates and prognostic significance. Am Heart J 2003; 145: 292-9. (Pubitemid 36207951)
39. Appleton CP, Hatle LK, Popp RL. Relation of transmitral flow velocity patterns to left ventricular diastolic function: new insights from a combined hemodynamic and Doppler echocardiographic study. J Am Coll Cardiol 1988; 12: 426-40.
40. Giannuzzi P, Imparato A, Temporelli PL, et al. Doppler-derived mitral deceleration time of early filling as a strong predictor of pulmonary capillary wedge pressure in postinfarction patients with left ventricular systolic dysfunction. J Am Coll Cardiol 1994; 23: 1630-7. (Pubitemid 24182130)
41. Pozzoli M, Capomolla S, Pinna G, Cobelli F, Tavazzi L. Doppler echocardiography reliably predicts pulmonary artery wedge pressure in patients with chronic heart failure with and without mitral regurgitation. J Am Coll Cardiol 1996; 27: 883-93.
42. Vanoverschelde JL, Raphael DA, Robert AR, Cosyns JR. Left ventricular filling in dilated cardiomyopathy: relation to functional class and hemodynamics. J Am Coll Cardiol 1990; 15: 1288-95.
43. Tabet JY, Logeart D, Geyer C, et al. Comparison of the prognostic value of left ventricular filling and peak oxygen uptake in patients with systolic heart failure. Eur Heart J 2000; 21: 1864-71.
44. Pinamonti B, Di Lenarda A, Sinagra G, Camerini F. Restrictive left ventricular filling pattern in dilated cardiomyopathy assessed by Doppler echocardiography: clinical, echocardiographic and hemodynamic correlations and prognostic implications. J Am Coll Cardiol 1993; 22: 808-15. (Pubitemid 23256944)
45. Pinamonti B, Zecchin M, Di Lenarda A, Gregori D, Sinagra G, Camerini F. Persistence of restrictive left ventricular filling pattern in dilated cardiomyopathy: an ominous prognostic sign. J Am Coll Cardiol 1997; 29: 604-12. (Pubitemid 27116104)
46. Traversi E, Pozzoli M, Cioffi G, et al. Mitral flow velocity changes after 6 months of optimized therapy provide important hemodynamic and prognostic information in patients with chronic heart failure. Am Heart J 1996; 132: 809-19. (Pubitemid 26366981)
47. Temporelli PL, Corrà U, Imparato A, Bosimini E, Scapellato F, Giannuzzi P. Reversible restrictive left ventricular diastolic filling with optimized oral therapy predicts a more favorable prognosis in patients with chronic heart failure. J Am Coll Cardiol 1998; 31: 1591-7. (Pubitemid 28273303)
48. Perkan A, Di Lenarda A, Sinagra G, et al. Predictive value of heart rate in dilated cardiomyopathy treated with metoprolol. G Ital Cardiol 1997; 27: 1106-12. (Pubitemid 27507921)
49. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992; 20: 248-54.
50. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334: 1349-55. (Pubitemid 26152713)
51. Sinagra G, Rakar S, Zecchin M, et al. Nonpredictive value of fibrosis in dilated cardiomyopathy treated with metoprolol. Cardiovasc Pathol 1996; 5: 21-8.
52. Pinamonti B, Perkan A, Di Lenarda A, Gregori D, Sinagra G. Dobutamine echocardiography in idiopathic dilated cardiomyopathy: clinical and prognostic implications. Eur J Heart Fail 2002; 4: 49-61. (Pubitemid 34113329)
53. Scrutinio D, Napoli V, Passantino A, Ricci A, Lagioia R, Rizzon P. Low-dose dobutamine responsiveness in idiopathic dilated cardiomyopathy: relation to exercise capacity and clinical outcome. Eur Heart J 2000; 21: 927-34. (Pubitemid 30307422)
54. Ramahi TM, Longo MD, Cadariu AR, et al. Dobutamine-induced augmentation of left ventricular ejection fraction predicts survival of heart failure patients with severe non-ischemic cardiomyopathy. Eur Heart J 2001; 22: 849-56.
55. Pratali L, Picano E, Otasevic P, et al. Prognostic significance of the dobutamine echocardiography test in idiopathic dilated cardiomyopathy. Am J Cardiol 2001; 88: 1374-8.
56. Hofmann T, Meinertz T, Kasper W, et al. Mode of death in idiopathic dilated cardiomyopathy: multivariate analysis of prognostic determinants. Am Heart J 1988; 116: 1455-63. (Pubitemid 19009845)
57. Meinertz T, Hofmann T, Kasper W, et al. Significance of ventricular arrhythmias in idiopathic dilated cardiomyopathy. Am J Cardiol 1984; 53: 902-7.
58. Keogh AM, Baron DW, Hickie JB. Prognostic guides in patients with idiopathic or ischemic dilated cardiomyopathy assessed for cardiac transplantation. Am J Cardiol 1990; 65: 903-8.
59. Das SK, Mordy F, Di Carlo L, et al. Prognostic usefulness of programmed ventricular stimulation in idiopathic dilated cardiomyopathy without symptomatic ventricular arrhythmias. Am J Cardiol 1986; 58: 998-1000.
60. Morgera T, Di Lenarda A, Rakar S, et al. Substrate and prognostic impact of ventricular tachycardia in dilated cardiomyopathy. (abstr) Eur J Heart Fail 2002; 1 (Suppl 1): 63.
61. Caruso AC, Marcus FI, Hahn EA, et al. Predictors of arrhythmic death and cardiac arrest in the ESVEM trial. Circulation 1997; 96: 1888-92.
62. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303-10.
63. Grimm W, Hoffmann JJ, Muller HH, Maisch B. Implantable defibrillator event rates in patients with idiopathic dilated cardiomyopathy, nonsustained ventricular tachycardia on Holter and a left ventricular ejection fraction below 30%. J Am Coll Cardiol 2002; 39: 780-7.
64. Zecchin M, Di Lenarda A, Bonin M, et al. Incidence and predictors of sudden cardiac death during long term follow-up in patients with dilated cardiomyopathy on optimal medical therapy. Ital Heart J 2001; 2: 213-21.
65. Di Lenarda A, Zecchin M, Petz E, et al. Primary prevention of sudden death in patients with dilated cardiomyopathy: preliminary data from the Registry of Heart Muscle Disease of Trieste. (abstr) Eur J Heart Fail 2002; 1 (Suppl 1): 65.
66. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336: 525-33.
67. Di Lenarda A, Driussi M, Carniel E, et al. Digoxin withdrawal in dilated cardiomyopathy patients following improvement on optimal medical treatment including chronic beta-blockade. (abstr) Circulation 2002; 106 (Suppl II): II-613.